Article
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
The Lancet. Oncology - 1 May 2016
Planchard David, Kim Tae Min, Mazieres Julien, Quoix Elisabeth, Riely Gregory, Barlesi Fabrice, Souquet Pierre-Jean, Smit Egbert F, Groen Harry J M, Kelly Ronan J, Cho B C, Socinski Mark A, Pandite Lini, Nase Christine, Ma Bo, D'Amelio Anthony, Mookerjee Bijoyesh, Curtis C Martin, Johnson Bruce E
Abstract excerpt
BACKGROUND: Activating BRAF(V600E) (Val600Glu) mutations are found in about 1-2% of lung adenocarcinomas, which might provide an opportunity for targeted treatment in these patients. Dabrafenib is an oral selective inhibitor of BRAF kinase. We did a trial to assess the clinical activity of dabrafenib in patients with advanced non-small-cell lung cancer (NSCLC) positive for the BRAF(V600E) mutation. METHODS: In...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.